Regeneron Pharmaceuticals, Inc.
REGNNasdaqCIK 872589HealthcareFiscal year ends Dec 31
Latest reported revenue, Q2 FY2026$4.29bnRevenue, Q2 FY2026, three months to 2026-06-30$4.29bn. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 30, 2026.Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenue$4.29bnRevenue, Q2 FY2026, three months to 2026-06-30$4.29bn. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure+16.7% on a year earlier - Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
- Operating margin30.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $1.29bn. XBRL concept
us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $4.29bn. XBRL conceptus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure+0.8 pts on a year earlier - Net margin30.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $1.30bn. XBRL concept
us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $4.29bn. XBRL conceptus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure−7.6 pts on a year earlier - Diluted EPS$12.23Diluted EPS, Q2 FY2026, three months to 2026-06-30$12.23 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure−4.5% on a year earlier - Free cash flow$572.8mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $813.0m. XBRL concept
us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000872589-26-000025. Derived: 6-month figure less the 3-month figure.Capital expenditure: $240.2m. XBRL conceptus-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-07-30, accession 0000872589-26-000025. Derived: 6-month figure less the 3-month figure.Report this figure−38.1% on a year earlier
Last eight quarters
Full statements| Line item | Unit | Q3 FY20242024-09-30 | Q4 FY20242024-12-31 | Q1 FY20252025-03-31 | Q2 FY20252025-06-30 | Q3 FY20252025-09-30 | Q4 FY20252025-12-31 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $m | 3,721Revenue, Q3 FY2024, three months to 2024-09-30$3.72bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | 3,789Revenue, Q4 FY2024, three months to 2024-12-31$3.79bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 3,029Revenue, Q1 FY2025, three months to 2025-03-31$3.03bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 3,676Revenue, Q2 FY2025, three months to 2025-06-30$3.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | 3,754Revenue, Q3 FY2025, three months to 2025-09-30$3.75bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | 3,884Revenue, Q4 FY2025, three months to 2025-12-31$3.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 3,605Revenue, Q1 FY2026, three months to 2026-03-31$3.61bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 4,291Revenue, Q2 FY2026, three months to 2026-06-30$4.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | 31.7%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $1.18bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Revenue: $3.72bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | 26.1%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $990.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Revenue: $3.79bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 19.5%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $591.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Revenue: $3.03bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 29.4%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $1.08bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $3.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | 27.3%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $1.03bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Revenue: $3.75bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | 22.7%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $879.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Revenue: $3.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 17.8%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $642.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Revenue: $3.61bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 30.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $1.29bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $4.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | |
| Net margin | % | 36.0%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $1.34bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Revenue: $3.72bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | 24.2%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $917.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Revenue: $3.79bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 26.7%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $808.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $3.03bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 37.9%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $1.39bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $3.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | 38.9%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $1.46bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Revenue: $3.75bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | 21.7%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $844.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Revenue: $3.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 20.2%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $727.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $3.61bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 30.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $1.30bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Revenue: $4.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | |
| Diluted EPS | $ per share | 11.54Diluted EPS, Q3 FY2024, three months to 2024-09-30$11.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | not reported (Diluted EPS not reported) | 7.27Diluted EPS, Q1 FY2025, three months to 2025-03-31$7.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 12.81Diluted EPS, Q2 FY2025, three months to 2025-06-30$12.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | 13.62Diluted EPS, Q3 FY2025, three months to 2025-09-30$13.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0000872589-25-000028.Report this figure | not reported (Diluted EPS not reported) | 6.75Diluted EPS, Q1 FY2026, three months to 2026-03-31$6.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 12.23Diluted EPS, Q2 FY2026, three months to 2026-06-30$12.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000872589-26-000025.Report this figure | |
| Free cash flow | $m | 1,049Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $1.29bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0000872589-25-000028. Derived: 9-month figure less the 6-month figure.Capital expenditure: $241.9m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-10-28, accession 0000872589-25-000028. Derived: 9-month figure less the 6-month figure.Report this figure | 1,063Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $1.26bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Capital expenditure: $199.6m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 816Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $1.05bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Capital expenditure: $229.3m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 925Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $1.14bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000872589-26-000025. Derived: 6-month figure less the 3-month figure.Capital expenditure: $219.0m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-07-30, accession 0000872589-26-000025. Derived: 6-month figure less the 3-month figure.Report this figure | 1,417Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $1.62bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0000872589-25-000028. Derived: 9-month figure less the 6-month figure.Capital expenditure: $201.4m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-10-28, accession 0000872589-25-000028. Derived: 9-month figure less the 6-month figure.Report this figure | 922Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $1.17bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Capital expenditure: $248.7m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-04, accession 0000872589-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure | 848Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $1.08bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Capital expenditure: $230.6m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-04-29, accession 0000872589-26-000016.Report this figure | 573Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $813.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000872589-26-000025. Derived: 6-month figure less the 3-month figure.Capital expenditure: $240.2m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-07-30, accession 0000872589-26-000025. Derived: 6-month figure less the 3-month figure.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $bn | 16.1Revenue, FY2021, twelve months to 2021-12-31$16.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-05, accession 0001804220-24-000009.Report this figure | 12.2Revenue, FY2022, twelve months to 2022-12-31$12.17bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-05, accession 0001804220-25-000011.Report this figure | 13.1Revenue, FY2023, twelve months to 2023-12-31$13.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 14.2Revenue, FY2024, twelve months to 2024-12-31$14.20bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 14.3Revenue, FY2025, twelve months to 2025-12-31$14.34bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | 55.7%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $8.95bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-05, accession 0001804220-24-000009.Revenue: $16.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-05, accession 0001804220-24-000009.Report this figure | 38.9%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $4.74bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-05, accession 0001804220-25-000011.Revenue: $12.17bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-05, accession 0001804220-25-000011.Report this figure | 30.9%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $4.05bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008.Revenue: $13.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 28.1%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $3.99bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008.Revenue: $14.20bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 24.9%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $3.58bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008.Revenue: $14.34bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | |
| Net margin | % | 50.2%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $8.08bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-05, accession 0001804220-24-000009.Revenue: $16.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-05, accession 0001804220-24-000009.Report this figure | 35.6%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $4.34bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-05, accession 0001804220-25-000011.Revenue: $12.17bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-05, accession 0001804220-25-000011.Report this figure | 30.1%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $3.95bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008.Revenue: $13.12bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 31.1%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $4.41bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008.Revenue: $14.20bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 31.4%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $4.50bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-04, accession 0000872589-26-000008.Revenue: $14.34bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | |
| Diluted EPS | $ per share | 71.97Diluted EPS, FY2021, twelve months to 2021-12-31$71.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-05, accession 0001804220-24-000009.Report this figure | 38.22Diluted EPS, FY2022, twelve months to 2022-12-31$38.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-05, accession 0001804220-25-000011.Report this figure | 34.77Diluted EPS, FY2023, twelve months to 2023-12-31$34.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 38.34Diluted EPS, FY2024, twelve months to 2024-12-31$38.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 41.48Diluted EPS, FY2025, twelve months to 2025-12-31$41.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | |
| Free cash flow | $bn | 6.5Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $7.08bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-05, accession 0001804220-24-000009.Capital expenditure: $551.9m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2024-02-05, accession 0001804220-24-000009.Report this figure | 4.4Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $5.01bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-05, accession 0001804220-25-000011.Capital expenditure: $590.1m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2025-02-05, accession 0001804220-25-000011.Report this figure | 3.9Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $4.59bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-04, accession 0000872589-26-000008.Capital expenditure: $718.6m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 3.7Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $4.42bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-04, accession 0000872589-26-000008.Capital expenditure: $755.9m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure | 4.1Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $4.98bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-04, accession 0000872589-26-000008.Capital expenditure: $898.4m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-04, accession 0000872589-26-000008.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2020-06-09 | Sanofi10% owner | Sale | 120,234 | $597.48 | $71.8m | Form 4 |
| 2020-05-29 | Sanofi10% owner | Sale | 2,399,552 | $509.85 | $1.22bn | Form 4 |
| 2020-05-29 | Sanofi10% owner | Sale | 20,421,899 | $509.85 | $10.41bn | Form 4 |
| 2020-03-09 | Sanofi10% owner | Sale | 128,914 | $489.6532 | $63.1m | Form 4 |
| 2019-09-10 | Sanofi10% owner | Sale | 172,904 | $281.1491 | $48.6m | Form 4 |
| 2019-03-08 | Sanofi10% owner | Sale | 131,115 | $412.1673 | $54.0m | Form 4 |
| 2018-09-06 | Sanofi10% owner | Sale | 104,552 | $406.6804 | $42.5m | Form 4 |
| 2018-06-08 | Sanofi10% owner | Sale | 121,601 | $309.3057 | $37.6m | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 2,557 | $487.0108 | $1.2m | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 2,681 | $485.9939 | $1.3m | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 5,723 | $485.2798 | $2.8m | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 2,000 | $484.21 | $968.4k | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 4,485 | $482.8734 | $2.2m | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 1,302 | $481.6284 | $627.1k | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 21,360 | $480.7489 | $10.3m | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 28,586 | $479.9313 | $13.7m | Form 4 |
| 2017-08-25 | Sanofi10% owner | Purchase | 3,684 | $479.1912 | $1.8m | Form 4 |
| 2017-08-24 | Sanofi10% owner | Purchase | 6,960 | $488.574 | $3.4m | Form 4 |
| 2017-08-24 | Sanofi10% owner | Purchase | 8,860 | $487.5532 | $4.3m | Form 4 |
| 2017-08-24 | Sanofi10% owner | Purchase | 6,920 | $486.6264 | $3.4m | Form 4 |
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2026-06-30 | $5.68bn | 9,113,506 | Added+165,771 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $4.13bn | 6,629,759 | Reduced−25,154 | |
| Dodge & Cox | 2026-06-30 | $3.04bn | 4,871,137 | Added+412,899 | |
| STATE STREET CORP | 2026-06-30 | $3.01bn | 4,834,688 | Added+170,210 | |
| Invesco Ltd. | 2026-06-30 | $2.46bn | 3,940,665 | Added+2,216,187 | |
| JPMORGAN CHASE & CO | 2026-06-30 | $2.38bn | 3,774,199 | Reduced−537,607 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2026-06-30 | $1.98bn | 3,175,313 | Added+1,454,539 | |
| FRANKLIN RESOURCES INC | 2026-06-30 | $1.73bn | 2,771,839 | Added+49,768 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-06-30 | $1.63bn | 2,625,810 | Added+18,078 | |
| Nuveen, LLC | 2026-06-30 | $1.26bn | 2,019,974 | Reduced−45,090 |
Recent filings
All 1,914 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0611:51 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events | 0001104659-26-113895 |
| 2026-09-3020:14 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-112340 |
| 2026-07-3010:52 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0000872589-26-000025 |
| 2026-07-3010:48 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000872589-26-000023 |
| 2026-07-0611:00 ET | 8-K | 2.02 Results of operations | 0001104659-26-080562 |
| 2026-06-1720:05 ET | 8-K | 5.07 Shareholder vote results | 0001104659-26-075127 |
| 2026-04-2910:54 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0000872589-26-000016 |
| 2026-04-2910:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000872589-26-000014 |
| 2026-04-2420:02 ET | DEF 14A | Proxy statementPeriod 2026-06-12 | 0001308179-26-000340 |
| 2026-04-0811:05 ET | 8-K | 2.02 Results of operations | 0001104659-26-040661 |
Latest annual report
Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 4, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 872589
- Tickers
- REGN
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- NY
- Filer category
- Large accelerated filer
- Former names
- REGENERON PHARMACEUTICALS INC (to 2019-06-19)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. Listed shows no prices and gives no investment advice.